Cohort characteristics
| TA314 does not advise ICD (n=707) | TA314 advises ICD (n=319) | p Value | |
|---|---|---|---|
| Age (years) | 669 (5) | 706 (6) | <0.001 |
| Heart rate (bpm) | 75 (8) | 742 (1) | 0.52 |
| Systolic blood pressure (BP) (mm Hg) | 123 (8) | 1168 (12) | <0.001 |
| QRS interval (ms) | 1106 (1) | 1522 (13) | <0.001 |
| Haemoglobin (g/l) | 136 (1) | 135 (1) | 0.38 |
| eGFR (mL/kg/1.73 m2) | 562 (7) | 532 (9) | 0.008 |
| LVEDD (mm) | 562 (3) | 629 (5) | <0.001 |
| LVEF (%) | 347 (3) | 263 (4) | <0.001 |
| Ramipril dose (mg/day) | 5 (1) | 49 (2) | 0.73 |
| Bisoprolol dose (mg/day) | 38 (1) | 33 (2) | 0.038 |
| Furosemide dose (mg/day) | 516 (19) | 574 (29) | 0.094 |
| Diabetes (% (n)) | 286 (202) | 197 (63) | 0.003 |
| Ischaemic aetiology (% (n)) | 636 (450) | 599 (191) | 0.25 |
| CRT (% (n)) | 146 (103) | 564 (180) | <0.001 |
| ICD (% (n)) | 92 (65) | 235 (75) | <0.001 |
| NYHA class (% (n)) | <0.001 | ||
| I | 228 (161) | 166 (53) | |
| II | 484 (342) | 411 (131) | |
| III | 264 (187) | 423 (135) | |
| IV | 24 (17) | 0 | |
| ACEi/ARB use (% (n)) | 882 (623) | 886 (280) | 0.87 |
| β-blocker use (% (n)) | 82 (579) | 797 (252) | 0.39 |
| MRA use (% (n)) | 388 (274) | 475 (150) | 0.009 |
ARB, angiotensin receptor blocker; CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.